Candesartan: widening indications for this angiotensin II receptor blocker? - Wikidata - awgldk - TriplyDB

Candesartan: widening indications for this angiotensin II receptor blocker?

Candesartan: widening indications for this angiotensin II receptor blocker?

http://www.wikidata.org/entity/Q37534746

about

Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives.Candesartan cilexetil: an update.

P2860

Q34081808-25ACDD2A-0A5F-4AD1-9042-DBAB83F2FBC5 Q37886191-4F7A89E2-6EAC-4A8D-BDED-B2BA878B8479

P2860

Candesartan: widening indications for this angiotensin II receptor blocker?

http://www.wikidata.org/entity/Q37534746

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Candesartan: widening indications for this angiotensin II receptor blocker?

@en

Candesartan: widening indications for this angiotensin II receptor blocker?

@nl

type

label

Candesartan: widening indications for this angiotensin II receptor blocker?

@en

Candesartan: widening indications for this angiotensin II receptor blocker?

@nl

prefLabel

Candesartan: widening indications for this angiotensin II receptor blocker?

@en

Candesartan: widening indications for this angiotensin II receptor blocker?

@nl

P1433

Q37534746-37812809-9705-47CA-8221-F6A0EA6DF827

P1476

Q37534746-929B970C-E511-47D7-A330-DF295138D86B

P2093

Q37534746-07BB96F4-C304-4093-80D1-0F410C118CBB

Q37534746-5DC33100-610B-40F4-A44F-6C89ADA6A547

P2860

Q37534746-023A0E62-8691-4B83-9C24-AC15DE81ED57

Q37534746-0AB7803B-F951-43EC-95E1-C9ECF3DBDE22

Q37534746-17B207E7-6A47-4E42-A16B-DD859111B539

Q37534746-1A3DAFE0-7B36-4987-BB12-558DE841FB47

Q37534746-1E97B1D2-B14D-43FE-A190-A04BD9F2C9C8

Q37534746-1EAD1A2A-FFC9-4DFF-A9BB-CB07F49AB8C8

Q37534746-3AFC07AD-8396-47CD-A22E-836BC0535F84

Q37534746-4622B6D4-8CF1-4904-B0E9-C0E1E03A1709

Q37534746-49C57B70-B8C2-4F4C-9C64-8C2A6201B8C4

Q37534746-4C418A7D-231F-41A3-978E-C4225065C239

P304

Q37534746-3A2F3084-775A-4826-81D6-B6196DD5FA81

P31

Q37534746-364A3D06-482B-418D-94A3-586D0667FE1C

P356

Q37534746-00B673A8-3E58-44F7-AFEF-B5410AEB2B04

P407

Q37534746-D76777DD-D41A-4BE1-8916-C47119D8340F

P433

Q37534746-97BC8C81-53DF-4132-B56A-1336BD330788

P478

Q37534746-0E4DE3EA-D48E-4B14-B0CD-7BC8329CB3F8

P577

Q37534746-2928231D-F53D-42D0-9495-67633953EF47

P698

Q37534746-99416E93-0F20-4C73-9342-1C51179AB025

P356

14656560903092197

P1433

Expert Opinion on Pharmacotherapy

P1476

Candesartan: widening indications for this angiotensin II receptor blocker?

@en

P2093

B Mendis

http://www.w3.org/2001/XMLSchema#string

S R Page

http://www.w3.org/2001/XMLSchema#string

P2860

Leading causes of certification for blindness and partial sight in England & Wales

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Supramaximal dose of candesartan in proteinuric renal disease

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial I

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.

P304

1995-2007

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656560903092197

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19563275

http://www.w3.org/2001/XMLSchema#string